With the latest round of investments, Illumina Ventures has built up a genomic-focused fund of $560 million. The money will support early-stage companies that are developing life science tools, clinical diagnostics, and therapeutics platforms, as well as digital health and other genomics applications.

Illumina Ventures is an independently managed investment firm. Funding for the second fund is anchored by an investment from Illumina, with the rest committed by other strategic and financial advisors.

Illumina launches genomics incubator in China
Illumina has partnered with investment firm Sequoia Capital China to launch a new collaboration designed to create an incubator for startup companies...

Emedgene, Illumina partner on rare disease analysis
Emedgene and Illumina have partnered to interpret genomic data for rare diseases.

Illumina's Q2 revenue drops 25%
Illumina's revenue dropped 25% due to the impact of the COVID-19 pandemic on the company's business in the second quarter. The company's net income also...

Illumina introduces sequencing software for rare genetic diseases
Illumina has launched software that facilitates whole genome sequencing for rapid identification of rare genetic diseases.

Illumina Accelerator announces new genomics startups
Illumina has chosen seven companies to join the first global cohort of Illumina Accelerator, its startup incubator that partners with entrepreneurs to...